AnEnergy-Sustainable and Oxidative-Tolerant Nanofactoryof Therapeutic Proteins for Long-Acting Therapy of Inflammatory BowelDisease

What To Know

This paper reports an experimental “nanofactory” (NENFpro) built from a ZIF-8 scaffold that contains a plasmid encoding an anti-inflammatory deubiquitinase (OTUD1) plus an iridium-based nanozyme (IrNZ).

The authors describe how the nanozyme component protects plasmid integrity from oxidative damage and catalytically generates oxygen to support plasmid transcription locally in inflamed tissue, aiming for sustained in situ production of therapeutic protein for IBD.

The work is presented as a materials/engineered-biology proof of concept in an academic journal (ACS Nano). It focuses on the design and mechanistic rationale (antioxidant protection, oxygen generation, and plasmid-driven protein expression) rather than on late-stage clinical testing.

If you’re following new therapeutic platforms for IBD, this is an early-stage laboratory strategy for local, long-acting protein therapy using nanomaterials and gene-delivery concepts. It is not a tested clinical treatment and would require substantial additional preclinical safety and efficacy work before any human use could be considered.